Back to Results

Repligen Corporation (RGEN)

Repligen Corporation is a life sciences company focused on bioprocessing technologies and systems used across North America, Europe, the Asia Pacific, and other international markets. Its product portfolio includes hollow fiber consumables, chromatography systems and resins, filtration and cell retention systems, process analytics tools, and related laboratory and production products. Key offerings include the KRM chromatography system, OPUS pre-packed chromatography columns, XCell ATF Cell Retention Systems, TangenX cassettes, KrosFlo filtration systems, and several PATsmart and SoloVPE process monitoring products.

The company serves life sciences, biopharmaceutical, and diagnostics customers, as well as laboratory researchers and contract manufacturing organizations. Repligen markets its products under brands such as OPUS, XCell, TFDF, KrosFlo, SoloVPE, ProConnex, NGL-Impact, FlowVPE, and others. Incorporated in 1981 and headquartered in Waltham, Massachusetts, Repligen also maintains a collaboration with Navigo Proteins GmbH to develop affinity ligands.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-RGEN
$127.12
-5.5% Downside
Fair
$178.05
32.4% Upside
Undervalued
Good
—
—
—
0.0%
July 28, 2026
147.3x
3.6x
9.9x
8.207 B
7.474 B
7.7%
94.6%
7.9
—
206.3%
Send a message
Valuation • Fair Value

Repligen Corporation (NASDAQ-RGEN) Fair Value by Valuation Model

Compare the primary fair value estimate for Repligen Corporation (NASDAQ-RGEN) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$127.12

Estimated downside of 5.5% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$115.40

Discounted cash flow valuation reference.

Ben Graham Formula Value

$10.11

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$138.83

Comparable-company valuation reference.

Analyst Price Target

$178.05

Analysts imply upside of 32.4%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Repligen Corporation (NASDAQ-RGEN) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Repligen Corporation (NASDAQ-RGEN)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

763.3 M

Current operating scale indicator.

Revenue Forecast

820 M

Forward revenue estimate.

EBITDA

134.2 M

Current operating profitability reference.

EBITDA Forecast

167.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Repligen Corporation (NASDAQ-RGEN) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Repligen Corporation (NASDAQ-RGEN)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.61

No elevated caution signal from this screen.

Altman Z-Score

7.9

Relatively strong balance-sheet zone.

FCF / Net Income

206.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Repligen Corporation (NASDAQ-RGEN). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Repligen Corporation (NASDAQ-RGEN)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 28, 2026

Days to Earnings

7

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Repligen Corporation (NASDAQ-RGEN), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Repligen Corporation (NASDAQ-RGEN) Stock Forecast & Technical Outlook

Review Repligen Corporation (NASDAQ-RGEN) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Repligen Corporation (NASDAQ-RGEN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Repligen Corporation (NASDAQ-RGEN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Repligen Corporation (NASDAQ-RGEN) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Repligen Corporation (NASDAQ-RGEN) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Repligen Corporation (NASDAQ-RGEN) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Repligen Corporation (NASDAQ-RGEN)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Repligen Corporation (NASDAQ-RGEN) has a Strong Buy consensus, with 15 buy, 3 hold and 0 sell recommendations in the current data set.

Buy 15
Hold 3
Sell 0
FAQ • Fast Investor Answers

Repligen Corporation (NASDAQ-RGEN) Stock FAQ

Quick answers about Repligen Corporation (NASDAQ-RGEN) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$127.12
Estimated downside 5.5%
Valuation Rating
Overvalued
Estimated downside of 5.5%
Analyst Target
$178.05
Implied upside 32.4%
Financial Health
Good
Current financial-health read

The current fair value estimate for Repligen Corporation (NASDAQ-RGEN) is $127.12. This implies an estimated downside of 5.5% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 5.5% versus the current market price.

The available analyst price target for Repligen Corporation (NASDAQ-RGEN) is $178.05. The analyst target implies estimated upside of 32.4%.

The current financial health read for Repligen Corporation (NASDAQ-RGEN) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Repligen Corporation (NASDAQ-RGEN) is July 28, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Repligen Corporation (NASDAQ-RGEN) is 147.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Repligen Corporation is 8.207 B.

The current enterprise value listed for Repligen Corporation is 7.474 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Repligen Corporation is NASDAQ-RGEN, and the stock is listed on NASDAQ.

Repligen Corporation (NASDAQ-RGEN) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Repligen Corporation is 7.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Repligen Corporation is 94.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks on NASDAQ View more

Illumina Inc (ILMN) Illumina Inc (ILMN)
Medpace Holdings Inc (MEDP) Medpace Holdings Inc (MEDP)
ICON PLC (ICLR) ICON PLC (ICLR)
Bio-Techne Corp (TECH) Bio-Techne Corp (TECH)
Tempus AI Inc (TEM) Tempus AI Inc (TEM)
Bruker Corporation (BRKR) Bruker Corporation (BRKR)
10X Genomics Inc (TXG) 10X Genomics Inc (TXG)
Sotera Health Co (SHC) Sotera Health Co (SHC)
Adaptive Biotechnologies Corp (ADPT) Adaptive Biotechnologies Corp (ADPT)
Maravai Lifesciences Holdings Inc (MRVI) Maravai Lifesciences Holdings Inc (MRVI)
Abcellera Biologics Inc (ABCL) Abcellera Biologics Inc (ABCL)
Fortrea Holdings Inc (FTRE) Fortrea Holdings Inc (FTRE)
BioLife Solutions Inc (BLFS) BioLife Solutions Inc (BLFS)
Personalis Inc (PSNL) Personalis Inc (PSNL)
Azenta Inc (AZTA) Azenta Inc (AZTA)
Cryoport Inc (CYRX) Cryoport Inc (CYRX)
Evotec SE ADR (EVO) Evotec SE ADR (EVO)
Cytek Biosciences Inc (CTKB) Cytek Biosciences Inc (CTKB)
Mesa Laboratories Inc (MLAB) Mesa Laboratories Inc (MLAB)
Pacific Biosciences of California (PACB) Pacific Biosciences of California (PACB)
Standard Biotools Inc (LAB) Standard Biotools Inc (LAB)
OmniAb Inc (OABI) OmniAb Inc (OABI)
Alpha Teknova Inc (TKNO) Alpha Teknova Inc (TKNO)
Nautilus Biotechnology Inc (NAUT) Nautilus Biotechnology Inc (NAUT)